Home
overview

SMi Group announces the return of its 8th annual RNA Therapeutics conference to London on the 22nd - 23rd of February 2017. Technology in RNA interference, oligonucleotides and mRNA has revolutionised the way infectious disease, cancer and neurological disorders are treated. It is now possible to target previously ‘un-druggable’ sites, therefore expanding the range of therapeutics that selectively silence genes before the disease develops.


AstraZeneca has added another $140 million to its $1.2 billion investment into Moderna Therapeutics’ mRNA technology*. Consequently continued collaboration between pharmaceutical giants and innovative biotechnology companies, has created considerable funding and buzz around RNA research.

The main challenge in RNA therapeutics continues to be the delivery of RNA based drugs to target sites outside the liver. Join us in exploring the different delivery systems in use and in development such as transportation with nanoparticles and the ability to enhance drug stability.

We will be reviewing clinical trial updates in RNA- based therapeutics and discussing the current regulations involved in getting drug approval. Learn about the main developments currently shaping the industry and how best to tackle challenges facing RNA therapeutics.


*https://www.cambridgenetwork.co.uk/news/astrazeneca-and-moderna-therapeutics-announce-new-collaboration/
 

  • Overcome challenges in regulation and maximise therapeutics manufacturing by seeing BioNTech up-scale personalized RNA Nanomedicines in cancer Vaccines.
  • Gain practical skills from MiNA Therapeutics on RNA activation and the results of their clinical trials. They will be discussing the impact saRNA is having on patients suffering from liver disease- discover how you too can strengthen your approach to clinical trials.
  • AstraZeneca will be Exploring emerging antisense oligonucleotide drugs and ways in you can improve drug delivery and optimise clinical results.
  • Hear from GSK on the progress of their 5 year IMI COMPACT project and the results of their collaboration with other pharmaceutical companies into the optimisation of oligonucleotide drug delivery.
  • Find out how to strategically plan and execute a successful clinical study with an exclusive update from Exicure on their unique nucleic acid based topical treatment for psoriasis.
     

Advanced Cell Diagnostics SRL; Affymetrix; Aldevron; Alexion GmbH; Amgen Gmb H; Aptamer group; Avencia Group; Bayer Pharma AG; BioNTech AG; Boehringer Ingelheim; Boehringer Ingelheim Pharma GmbH & Co. KG; Boult Wade Tennant; Covington & Burling Llp; Cristal Therapeutics; CureVac GmbH; Drug Target Review; Erdmann Technologies GmbH; Institute for Research in Biomedicine (IRB Barcelona); K.U.Leuven; Karolinska Institutet; MiNA Therapeutics; ProQR Therapeutics; RCSI Royal College of Surgeons in Ireland,; Rigontec GmbH; Sarepta Therapeutics; Silence Therapeutics GmbH; Silenseed; THERMO FISHER SCIENTIFIC; ThermoFisher; Translational Oncology (TRON); Universita Magna Graecia - Catanzaro; Universite Paris Sud; University of Amsterdam; University Of Twente / 20Med; Vascular and Genomic Center Changhua Christian Hospital;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Nagy Habib

Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

9:10 RNA activation and its clinical application

Nagy Habib

Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

  • Small activating RNA (saRNA) can activate most of the coding and non-coding genome
  • CEBPa is a transcriptional activation of the hepatocyte that can be upregulated with saRNA
  • Clinical application: SARNA CEBPa offers a therapeutic opportunity for patients with NASH and liver failure
  • 9:50 Collaborating to deliver macromolecules across biological barriers – a review of IMI COMPACT

    Steve Hood

    Steve Hood, Director, Scinovo, GSK
    View Bio

  • What are the challenges of Oligo Delivery?
  • How do we optimise delivery
  • Who are COMPACT and what have we achieved?
  • 10:30 Morning Coffee

    11:00 Delivery of mRNA using the Viromer® system

    Steffen Panzner

    Steffen Panzner, Managing Director, Lipocalyx
    View Bio

  • A lesson learned from a virus: the Viromer delivery system
  • Formulation aspects of Viromer nanoparticles
  • Viromer: mRNA delivery on multiple routes
  • 11:40 Therapeutic antisense oligonucleotides in oncology

    Mark Edbrooke

    Mark Edbrooke, Senior Principal Scientist, AstraZeneca

  • The progress of emerging antisense oligonucleotide drugs and the targeting of un-druggable sites in oncology
  • Methods in drug delivery
  • Update on clinical trials in the field
  • 12:20 Networking Lunch

    13:30 RNA Therapeutics Harnessing the Potential of Locked

    Bo Rode Hansen

    Bo Rode Hansen, Director, Technology and Partnered Discovery, Santaris Pharma A/S
    View Bio

  • Exciting new insights into RNA Therapeutics drug discovery
  • Locked Nucleic acids: an update on how they are drug candidates for diseases with difficult targets
  • Next generation drugs and how they are transforming the treatment of diseases
  • New concepts to conducting drug discovery and optimising the process
  • 14:10 Sites of RNA silencing: Cell entry of exosomes as a novel paradigm for therapeutic RNA delivery

    Nicole meisner-kober

    Nicole meisner-kober, Senior Investigator, Novartis Institutes for Biomedical Research

  • Recent data on how exosomes have evolved a specific route for cell entry
  • Improvements in subcellular targeting to directly improve the therapeutic index and thus the clinical viability of siRNA therapies
  • The inefficiencies of some liposomal delivery vehicles in delivering siRNA to the endoplasmic reticulum
  • Next generation RNA delivery vehicles- models to enhance the targeting of translation and RNA silencing sites
     
  • 14:50 Afternoon Tea

    15:20 RNAi and tumor microenvironment: pre-clinical and clinical evidence

    Amotz Shemi

    Amotz Shemi, CEO, Silenseed

  • The case of silencing mutated KRAS
  • Prolonged drug release continuously affects the tumor microenvironment
  • RNAi and immunotherapy
     
  • 16:00 Individualized mRNA-based cancer immunotherapy

    Andreas Kuhn

    Andreas Kuhn, Vice President RNA Biochemistry & Manufacturing, BioNTech

  • Regulatory framework for mRNA-based therapeutics
  • Optimisation of mRNA for therapeutic application
  • GMP manufacturing of mRNA
  • The IVAC MUTANOME concept
  • First clinical experience with mRNAs in individualised
    cancer immunotherapy
  • 16:40 Chairman’s Closing Remarks and Close of Day One

    Nagy Habib

    Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Heinrich Haas

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG
    View Bio

    9:10 Antisense in the fourth decade: Third generation antisense (3GA) fulfi lling the promise

    Sudhir Agrawal

    Sudhir Agrawal, President & C S O, Idera Pharmaceuticals

  • First report of antisense in 1978 and the journey so far
  • Various mechanisms of action of oligonucleotides have been reported
  • Agonists and Antagonists of TLRs that are in clinical development
  • The design of 3GA is optimized to realize the potential of antisense
  • 9:50 Interacting with the medicines regulator on RNAi therapies

    John Johnston

    John Johnston, Clinical Assessor, Biologicals & Biotechnology Unit, MHRA

  • A brief description of the regulatory environment
  • How to interact with the regulator
  • Some thoughts on reporting clinical data
  • 10:30 Morning Coffee

    11:40 Nano-therapeutics; the best of all possible worlds?

    Andrew Miller

    Andrew Miller, CSO, KP Therapeutics Ltd

     

  • New delivery systems for RNAi effectors usually result from horizontal not vertical developments
  • The need for vertical developments in nanoparticle mediated RNAi effector delivery
  • A rational framework for vertical developments
  • The potential power of Image guidance in nanoparticle mediated RNAi effector delivery
     
  • 12:20 Networking Lunch

    13:30 Intravenously injectable RNA Nanomedicines as cancer vaccines: case study with RNA-Lipoplexes

    Heinrich Haas

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG
    View Bio

  • Proceedings in development of nucleic acid based nanomedicines
  • RNA delivery technologies: challenges and opportunities
  • mRNA for cancer vaccination
  • Formulation development and preclinical proof-of concept for RNA-lipoplex formulations
  • GMP manufacturing and clinical testing of RNA-lipoplex products
  • 14:10 The challenges and lessons learnt about the delivery of small and large nucleic acids to cancers

    Sanyogitta Puri

    Sanyogitta Puri, Associate Prinicipal Scientist, AstraZeneca

  • Formulation of siRNA vs plasmid
  • mRNA delivery to tumours
  • Identification of key quality attributes and correlation to in vitro/in vivo effi cacy
  • Key challenges for development and manufacturing therapeutics
  • 14:50 Afternoon Tea

    15:20 Protecting the kidney: using siRNA targeting p53 to prevent and ameliorate acute kidney injury and delayed graft functio

    Shai Erlich

    Shai Erlich, VP, Pharmaceutical Development, Quark Biotech Inc

  • Taking advantage of the natural distribution of siRNA to renal tissue
  • The therapeutic approach of temporary p53 inhibition to prevent acute tissue damage
  • Challenges encountered along the journey to phase III clinical trials
  • Detailed results from a large Phase II clinical trial aimed at prevention of Delayed Graft Function in patient receiving kidney transplant from deceased donors
  • 16:00 Spherical Nucleic Acids:Structures for topical gene regulation

    David Giljohann

    David Giljohann, CEO, Exicure Inc.

  • Spherical Nucleic Acids (SNAs) are Three-dimensional arrangements of nucleic acids
  • SNAs effectively enter cells and tissues through Scavenger Receptors
  • Local, topical application of SNAs have allowed for early clinical trials
  • A Phase I microplaque study in patients with psoriasis was completed successfully and will be discussed
  • 16:40 Protecting your innovative products and methods: How to patent RNA therapeutics

    Mark  Chapman

    Mark Chapman, Partner, Carpmaels & Ransford

  • Update on relevant developments at the European Patent Office (EPO) and elsewhere
  • Understanding the ‘problem-and-solution’ approach applied by the EPO
  • How to draft successful patent specifi cations for RNA therapeutics
  • 17:20 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Bo Rode Hansen

    Bo Rode Hansen

    Director, Technology and Partnered Discovery, Santaris Pharma A/S
    Heinrich Haas

    Heinrich Haas

    VP RNA Formulation and Drug Developement , BioNTech AG
    John Johnston

    John Johnston

    Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
    Nicole meisner-kober

    Nicole meisner-kober

    Senior Investigator, Novartis Institutes for Biomedical Research
    Steffen Panzner

    Steffen Panzner

    Managing Director, Lipocalyx
    Steve Hood

    Steve Hood

    Director, Scinovo, GSK

    Amotz Shemi

    CEO, Silenseed
    Amotz Shemi

    Dr. Amotz Shemi is the Chief Executive Officer and a co-founder in Silenseed. Prior to Silenseed, Dr. Shemi served as a Senior VP Technologies in Medinol LTD, a leading medical-stent company for cardiovascular and gastroenterology diseases, and beforehand as the CEO of Color Chip, a leader in Ion-exchange based Planar Lightwave Circuits (PLC); Dr. Shemi brings with him 25 years of experience in end-to-end management from concept level via development, regulatory approvals to actual sales. Shemi received his PhD degree in Physics and Astrophysics from the Tel Aviv University in Israel. Dr. Shemi is a lead inventor of more than dozen patents in the RNAi-delivery field, and an author and co-author of about 40 scientific papers.

    Andrew Miller

    CSO, KP Therapeutics Ltd
    Andrew Miller

    Prof Miller is a leading chemist expert in the understanding and exploitation of molecular mechanisms in biology. The overall goal of his academic research has been and continues to be the design and creation of advanced therapeutics and diagnostics that address unmet medical need in the management of chronic diseases. From 1990-2010, Prof Miller was a member of academic staff in the Chemistry Department of Imperial College London (UK) where he became full Professor of Organic Chemistry & Chemical Biology in 2002, plus founding Director of the Imperial College Genetic Therapies Centre from 1998. Since 2010, Prof Miller has been based at King’s College London from where he has been developing his career as an academic entrepreneur, this year founding KP Therapeutics Ltd. The company’s Bio-Nano pipeline of potential products in discovery & development all derives from the best of Prof Miller’s personal and collaborative academic research work over the past two decades, involving a research spend of at least £20 million.

    Andrew Miller

    CSO, KP Therapeutics Ltd
    Andrew Miller

    Bo Rode Hansen

    Director, Technology and Partnered Discovery, Santaris Pharma A/S
    Bo Rode Hansen

    Dr. Bo Rode Hansen is Global Head of RNA Therapeutics Research at Roche and General Manager of Roche Innovation Center Copenhagen A/S. Prior to joining Roche, Bo spent years in discovery and drug hunting of new RNA Therapeutics. He was an executive and chair of the R&D committee of Santaris Pharma A/S, a leading company in the RNA Medicines space and owner of the Locked Nucleic Acid drug platform. Santaris Pharma was acquired by Roche in 2014.
    Dr. Hansen holds a Ph.D. in Biochemistry from the University of Copenhagen (Denmark) and an executive MBA from the Henley Business School (UK). Dr. Hansen is author and co-author of 40 peer reviewed publications, book chapters, issued patents and patent applications.
     

    David Giljohann

    CEO, Exicure Inc.
    David Giljohann

    David Giljohann is the CEO of Exicure, Inc., a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin at Northwestern University where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition.

    Heinrich Haas

    VP RNA Formulation and Drug Developement , BioNTech AG
    Heinrich Haas

    Heinrich Haas, Ph.D. has more than 18 years of experience in academic research and industrial pharmaceutical development. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems.

    His professional focus is on colloidal/nanoparticulate formulations for targeted drug delivery with therapeutic and diagnostic applications. Before joining BioNTech RNA Pharmaceuticals GmbH (former Ribological GmbH), he was responsible for a variety of projects in biopharmaceutical research and development, ranging from the exploration of novel colloidal therapeutic and diagnostic carriers to up-scaling and development of market-compliant manufacturing methods for liposome products. After joining BioNTech RNA Pharmaceuticals GmbH in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules. Heinrich is also the Head of IMP manufacturing at BioNTech RNA Pharmaceuticals GmbH. He has an active record of publications in peer-reviewed journals (30+) and patent applications (10+) in the field of drug delivery.

    Jeffrey Ulmer

    Head Preclinical R&D, GSK
    Jeffrey Ulmer

    Dr. Jeffrey Ulmer received his B.Sc. with honours from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines. He is currently Head, Preclinical R&D, GSK Vaccines.

    John Johnston

    Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
    John Johnston

    Mark Chapman

    Partner, Carpmaels & Ransford
    Mark  Chapman

    Mark is an experienced specialist Biotech patent attorney, based at Carpmaels & Ransford (a European IP firm) in London. Mark’s career as a patent attorney spans 15 years, ever since studying Molecular & Cellular Biochemistry at Oxford University, and graduating in 2001. During this time his practice has focused heavily on assisting companies developing nucleic acid therapeutics and diagnostics. Mark’s work in recent years has included the patent protection in Europe and elsewhere of Mipomersen (Kynamro®), Nusinersen and Volanesorsen (all Ionis Pharmaceuticals-developed antisense oligonucleotide therapeutics), along with the protection of numerous other candidate therapeutics for Ionis Pharmaceuticals. Mark also works closely with Regulus Therapeutics, for example prosecuting and defending European patents in Stanford University’s ‘Sarnow’ patent estate (relating to the use of miR-122 inhibitors for HCV treatment) for Regulus as licensee. Mark’s recent experience also includes prosecuting and defending European patents in Stanford University’s ‘Quake’ patent estate (relating to NIPT methods based on cffDNA in maternal blood) for licensee client Verinata Health (Illumina). Mark has also prepared and filed numerous successful oppositions to third party patent applications and patents, working to secure freedom to operate for his innovator clients.

    Mark Edbrooke

    Senior Principal Scientist, AstraZeneca
    Mark Edbrooke

    Mark Edbrooke earned his PhD in molecular biology from the University of London. He ran a transnational Gene Interference functional genomics department at GSK that generated target identification and validation data for all therapeutic areas across the company (e.g. oncology, cardiovascular, respiratory, neurology and infectious diseases). He then founded and led a Discovery Performance Unit (DPU) within GSK focused on the development of therapeutic siRNAs and, latterly, on therapeutic antisense oligonucleotides. He recently joined AstraZeneca (AZ) and is involved in AZ’s alliances with Ionis Pharmaceuticals, Regulus Therapeutics, and Moderna Therapeutics.

     

    Nagy Habib

    Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
    Nagy Habib

    Professor Nagy Habib is Head of HPB Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. He is co-founder of several biotech companies: EMcision Ltd, OmniCyte Ltd, MiNA Therapeutics Ltd, Apterna Ltd, Medeva Plc and Bioenvision Ltd. Previously he was Pro-Rector for Commercial Affairs at Imperial College London.
     

    He is a translational researcher who pioneered the first clinical trial of the use of plasmid and adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was the Principal Investigator of world first clinical trials published on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency and CD34+ cells for patients with stroke.
    He was the inventor and co-author on the first publication to describe the use of radiofrequency energy in devices for liver surgery (Habib 4X), and interventional endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA).
     

    Professor Habib holds a gold award from the Advisory Committee for Clinical Excellence which is given to recognise and reward the exceptional contribution of NHS consultants, over and above that normally expected in a job, to the values and goals of the NHS and to patient care, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine.
    In the 2014 Research Excellence Frame work (REF) exercise, which is the system for assessing the quality of research in UK in higher education institutions, Professor Habib was rated as a 4* researcher which is the highest ranking. His work on radiofrequency ablation was selected among those that have had the most “Impact on Society” and was ranked 1 with a score of 93%. In January 2015 he was elected as a Foreign Member by the prestigious French Académie Nationale de Chirurgie.
     

    Nicole meisner-kober

    Senior Investigator, Novartis Institutes for Biomedical Research
    Nicole meisner-kober

    Sanyogitta Puri

    Associate Prinicipal Scientist, AstraZeneca
    Sanyogitta Puri

    Shai Erlich

    VP, Pharmaceutical Development, Quark Biotech Inc
    Shai Erlich

    Shai Erlich is the President of Quark USA Operations and Chief Medical Officer. Dr. Erlich joined Quark in 1999 and since then has assumed several executive positions including Director of Portfolio Management,Product Development Strategic Planning and Vice president for Pharmaceutical Development . Dr. Erlich completed his studies at the School of Medicine at Ben Gurion University in Israel, and holds an M.Sc. in cancer genetics from the department of Human Genetics, Tel Aviv University, and a Ph.D. in Gene Therapy from the Department of Human Genetics, Mt Sinai Graduate School for Biomedical Sciences at the Mt. Sinai School of Medicine, New York.

    Steffen Panzner

    Managing Director, Lipocalyx
    Steffen Panzner

    Dr. Panzner is an expert in oligonucleotide delivery; author of more than 35 patent families and numerous scientific publications covering novel concepts for oligonucleotide delivery such as the Viromer® (virus-mimicking polymer) and the Smarticles® (amphoteric liposome) technology. Products based on these technologies are in phase 2 clinical trials or earlier stages of development.
     

    Dr. Panzner was Founder and CSO of Novosom AG between 1999 and 2010 and is Founder and CEO of Lipocalyx GmbH which started 2011. He also is a consultant and CMC expert for pharma and biotech companies as well as for VC firms.
     

    Steve Hood

    Director, Scinovo, GSK
    Steve Hood

    Steve studied for his PhD in Molecular Toxicology at Surrey University and joined Glaxo Group Research as a Post-Doctoral Fellow in 1993. Following the formation of GSK in 2001, Steve managed a team determining the drug-drug interaction liabilities while developing ADME strategies for the emerging GSK antibody portfolio.
    In 2010, Steve led a cross divisional team charged with understanding and overcoming the delivery issues inherent in GSK’s diverse oligo portfolio while helping to develop these molecules from earlt discovery to file. In 2011 Steve initiated the project that has grown into the IMI COMPACT collaboration and he is actively involved in facilitating the interaction between academia , biotech and large industry partners.
    Finally, for the past couple of years, Steve has been responsible for helping GSK Programme teams answer the fundamental questions of “Where does my drug go and what does it do when it gets there?” using a range of Bioimaging methodologies.
     

    Sudhir Agrawal

    President & C S O, Idera Pharmaceuticals
    Sudhir Agrawal

    Dr. Agrawal currently serves as President of Research at Idera Pharmaceuticals. He joined the company as a founding scientist, and has since served in various leadership roles, including Chief Scientific Officer and Chief Executive Officer. Over the last 25 years, Dr. Agrawal’s research focus has been in the field of nucleic acid therapeutics, including antisense technology and Toll-like receptor targeted compounds. Using a chemistry-based approach, a number of novel compounds have been created and reached clinical evaluation. He has authored over 300 research papers and reviews, and is the named inventor on over 400 issued or pending patents. Dr. Agrawal received his D.Phil. in Chemistry and conducted research at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, U.K. Working with Paul Zamecnik, MD, he conducted pioneering work in antisense technology. Based on this technology, Idera Pharmaceuticals was founded.

     

    Official Media Partner

    Official Publication

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    An Interview with Silenseed CEO, Amotz Shemi

    Download

    Media Partners


    Bio-ITWorld.com

    Official Media Partner
    http://www.Bio-ITWorld.com

    Weekly Update newsletter and News Bulletins cover the application of informatics, IT and computer science in biomedical research and drug discovery. As the life sciences become an increasingly quantitative discipline, Bio-IT World provides topical news coverage and analysis of cutting-edge technologies to handle the data deluge in petascale computing and the tools to deliver individualized medicine.

    Media Partners


    Int. J. of Data Mining and Bioinformatics

    Official Publication
    http://www.inderscience.com/ijdmb

    Mining bioinformatics data is an emerging area at the intersection between bioinformatics and data mining. The objective of IJDMB is to facilitate collaboration between data mining researchers and bioinformaticians by presenting cutting edge research topics and methodologies in the area of data mining for bioinformatics. This perspective acknowledges the inter-disciplinary nature of research in data mining and bioinformatics and provides a unified forum for researchers/practitioners/students/policy makers to share the latest research and developments in this fast growing multi-disciplinary research area.


    Int. J. of Bioinformatics Research and Applications

    Official Publication
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.

    Media Partners


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    EIN News

    Supporters
    http://www.einnews.com

    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    British Pharmacological Society

    Supporters
    http://www.bps.ac.uk

    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Labhoo

    Supporters
    http://www.labhoo.com



    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.